Table 1A

Baseline characteristics

StudiesN
(total)
n
(ULT)
Population, countryAge, yrs, mean (SD)Male,(%)Disease
duration, yrs,
mean (SD)
MedicationsQuality
Prescription claims
Sarawate et al, 200617 59422405Managed care database, USA57.4 (14.1)*76.4*NSAllopurinol4
Briesacher et al, 200818 9715MEDSTAT database, USA58.7 (0.14)77.5NSAllopurinol, uricosurics4
Harrold et al, 200924 4166Integrated delivery Systems, USA62 (14)75NSAllopurinol, probenecid, sulfinpyrazone4
Halpern et al, 200930 18 24310 070Claims database, USAMean 53.984.2NSAllopurinol4
Rashid et al, 201229 9288KPSC healthcare, USAMean 6078NSAllopurinol4
Horsburgh et al, 201419 27 243732Community pharmacy dispensing databases, New ZealandNA39.5†NSAllopurinol4
Singh, 201423 43Outpatient clinic, USA63.9 (9.9)67NSAllopurinol, febuxostat2
McGowan et al, 201622 34 63415 908HSE-PCRS scheme database, IrelandMean 65.2*73*NSAllopurinol, febuxostat, probenecid, sulfinpyrazone3
Tan et al, 201632 91Hospital clinics, Singapore53.5 (16.9)92.3NSAllopurinol, probenecid2
Solomon et al, 200821 9823Medicare and PACE enrollees, USAMean 7928†NSAllopurinol4
Park et al, 201226 352242Scott & White Health Plan, USA61.02 (15.33)*72.4*†NSAllopurinol, febuxostat, probenecid4
Zandman-Goddard et al, 201320 7644MHS database, IsraelNA72NSAllopurinol4
Mantarro et al, 201531 3727HSD database, ItalyMean 6580NSAllopurinol4
Rashid et al, 201527 8288Clinical and administrative databases, USANA79.80NSAllopurinol, febuxostat, probenecid4
Kuo et al, 201528 49 395GPRD database, UKNANANSULT4
Riedel et al, 200425 94825597IPA plans, USA51(11)*82.1*NSAllopurinol4
Pill counts
Lee et al, 201633 132Outpatient clinic, Korea51.9 (10.4)100100.0 (89.1)‡Allopurinol, febuxostat2
Self-report
Silva et al, 201035 34Outpatient, Spain57.1 (11.8)94.1†NSAllopurinol, benzbromarone1
Singh et al, 201634 499251People visiting the Gout and Uric Acid Education Society’s website, USA56.3 (12.6)*73.7*NSAllopurinol, febuxostat5
Interview
Martini et al, 201236 6056Community pharmacies, New ZealandMean 61*90*NSAllopurinol2
Sheng et al, 201438 16180†Gout Clinic, ChinaNANANSULD1
van Onna et al, 201537 1512Outpatient clinic and primary care practices, The Netherlands63 (12)*93.3*†11(7)*ULT2
  • *Data for total population.

  • †Calculated based on data provided in the article.

  • ‡Disease duration (months).

  • cross, cross-sectional; NA, not applicable; NS, not stated; ULD, urate-lowering drugs; ULT, urate-lowering therapy; yr, year.